CMC Biologies (formerly CMC Biopharmaceuticals A/S) has closed a share offering from lead investor Monitor Clipper. The round also included existing investor European Equity Partners (EEP) and other smaller investors.
Shares are sold by shares were held by CapMan Buyout X Fund A and CapMan Buyout X Fund B
Advent made a takeover offer of 165 pence per share in cash, which represents a 34% premium in July
Business strategy platform will expand its product and triple its team size
Fund targets companies operating in the healthcare industry, primarily pharma, medtech and outsourced services